Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2010

Open Access 01-12-2010 | Case report

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer

Authors: Ferdinando Riccardi, Giuseppe Di Lorenzo, Carlo Buonerba, Guglielmo Monaco, Roberto Monaco, Mimma Rizzo, Sarah Scagliarini, Florinda Scognamiglio, Marilena Di Napoli, Giacomo Carteni'

Published in: World Journal of Surgical Oncology | Issue 1/2010

Login to get access

Abstract

Background

Defining the optimal treatment for patients with inoperable non small cell lung cancer (NSCLC), presenting with metastatic mediastinal lymph nodes, is challenging. Nevertheless, preoperative chemotherapy or radiotherapy might offer a chance for these patients for radical surgical resection and, possibly, complete recovery.

Case Presentation

A 62-year old man with IIIA-N2 inoperable NSCLC was treated with first-line single agent docetaxel. A platinum-based treatment, though considered more active, was ruled out because of renal impairment. The patient tolerated the treatment very well and, although his initial response was not impressive, after 14 cycles he obtained a complete clinical response, which was confirmed pathologically after he underwent surgical lobectomy.

Conclusion

In non-operable NSCLC patients not eligible for a platinum-based treatment, single-agent docetaxel can provide complete pathologic responses. Failure to obtain a response after the first few cycles should not automatically discourage to continue treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Albain KS: Induction therapy followed by definitive local control for stage III non-small-cell lung cancer. A review, with a focus on recent trimodality trials. Chest. 1993, 103 (Suppl): 43-50S. 10.1378/chest.103.1_Supplement.43S. Albain KS: Induction therapy followed by definitive local control for stage III non-small-cell lung cancer. A review, with a focus on recent trimodality trials. Chest. 1993, 103 (Suppl): 43-50S. 10.1378/chest.103.1_Supplement.43S.
2.
go back to reference Eberhardt W, Gauler T, Pöttgen C, Krbek T, Korfee S, Stamatis G, Stuschke M: Multimodality treatment of stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol. 2007, 2 (5 Suppl): S35-6. 10.1097/01.JTO.0000268640.56073.d1.CrossRefPubMed Eberhardt W, Gauler T, Pöttgen C, Krbek T, Korfee S, Stamatis G, Stuschke M: Multimodality treatment of stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol. 2007, 2 (5 Suppl): S35-6. 10.1097/01.JTO.0000268640.56073.d1.CrossRefPubMed
3.
go back to reference Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarié E, Gouva S, Paillot N, Bréchot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchâtre M, Coëtmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C, French Thoracic Cooperative Group: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002, 20: 247-53. 10.1200/JCO.20.1.247.CrossRefPubMed Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarié E, Gouva S, Paillot N, Bréchot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchâtre M, Coëtmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C, French Thoracic Cooperative Group: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002, 20: 247-53. 10.1200/JCO.20.1.247.CrossRefPubMed
4.
go back to reference Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004, 292: 470-84. 10.1001/jama.292.4.470.CrossRefPubMed Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004, 292: 470-84. 10.1001/jama.292.4.470.CrossRefPubMed
5.
go back to reference Mattson KV, Abratt RP, ten Velde G, Krofta K: Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol. 2003, 14: 116-22. 10.1093/annonc/mdg009.CrossRefPubMed Mattson KV, Abratt RP, ten Velde G, Krofta K: Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol. 2003, 14: 116-22. 10.1093/annonc/mdg009.CrossRefPubMed
6.
go back to reference Georgoulias V, Pallis AG, Kourousis C, Alexopoulos A, Ardavanis A, Agelidou A, Agelidou M, Toumbis M, Tzannes S, Pavlakou G, Ziotopoulos P, Tzelepatiotis E, Samaras N: Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study. Clin Lung Cancer. 2003, 4: 288-93. 10.3816/CLC.2003.n.008.CrossRefPubMed Georgoulias V, Pallis AG, Kourousis C, Alexopoulos A, Ardavanis A, Agelidou A, Agelidou M, Toumbis M, Tzannes S, Pavlakou G, Ziotopoulos P, Tzelepatiotis E, Samaras N: Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study. Clin Lung Cancer. 2003, 4: 288-93. 10.3816/CLC.2003.n.008.CrossRefPubMed
7.
go back to reference Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005, 23: 190-6. 10.1200/JCO.2005.07.172.CrossRefPubMed Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005, 23: 190-6. 10.1200/JCO.2005.07.172.CrossRefPubMed
8.
go back to reference Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O: Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002, S69-74. 10.3816/CBC.2002.s.015. Suppl Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O: Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002, S69-74. 10.3816/CBC.2002.s.015. Suppl
Metadata
Title
Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer
Authors
Ferdinando Riccardi
Giuseppe Di Lorenzo
Carlo Buonerba
Guglielmo Monaco
Roberto Monaco
Mimma Rizzo
Sarah Scagliarini
Florinda Scognamiglio
Marilena Di Napoli
Giacomo Carteni'
Publication date
01-12-2010
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2010
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-8-8

Other articles of this Issue 1/2010

World Journal of Surgical Oncology 1/2010 Go to the issue